Patents by Inventor William W. Turner

William W. Turner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions for making and using anti-Myostatin antibodies
    Patent number: 11925683
    Abstract: Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and/or latent Myostatin and uses thereof.
    Type: Grant
    Filed: September 3, 2021
    Date of Patent: March 12, 2024
    Assignee: Scholar Rock, Inc.
    Inventors: Michelle Straub, Dong Yun Lee, William K. McConaughy, Katherine Jane Turner, Nagesh K. Mahanthappa, Justin W. Jackson
  • HEPATITIS B CORE PROTEIN MODULATORS
    Publication number: 20240025890
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Application
    Filed: September 1, 2023
    Publication date: January 25, 2024
    Inventors: William W. TURNER, Lee D. ARNOLD, Hans MAAG, Leping LI, Mark G. BURES, Simon Nicolas HAYDAR, Samson FRANCIS
  • Hepatitis b core protein modulators
    Patent number: 11814376
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Grant
    Filed: January 4, 2021
    Date of Patent: November 14, 2023
    Assignees: Assembly Biosciences, Inc., Indiana University Research and Technology Corporation
    Inventors: William W. Turner, Jr., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
  • HEPATITIS B CORE PROTEIN MODULATORS
    Publication number: 20230044112
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Application
    Filed: January 4, 2021
    Publication date: February 9, 2023
    Applicants: Assembly Biosciences, Inc., INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: William W. Turner, JR., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
  • HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS
    Publication number: 20230019129
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Application
    Filed: January 21, 2021
    Publication date: January 19, 2023
    Applicants: Indiana University Research and Technology Corporation, Assembly Biosciences, Inc.
    Inventors: William W. Turner, JR., Lee Daniel Arnold, Hans Maag, Adam Zlotnick
  • CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME
    Publication number: 20230012463
    Abstract: The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.
    Type: Application
    Filed: January 14, 2021
    Publication date: January 12, 2023
    Inventors: William W. Turner, Leping Li, Simon Nicolas Haydar, Mark G. Bures, Roopa Rai, Samson Francis, Lee D. Arnold
  • HEPATITIS B CORE PROTEIN MODULATORS
    Publication number: 20220023311
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.
    Type: Application
    Filed: January 14, 2021
    Publication date: January 27, 2022
    Inventors: William W. Turner, Lee D. Arnold, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Hans Maag, Lynne Bannen
  • Cyclic sulfamide compounds and methods of using same
    Patent number: 11078170
    Abstract: The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: August 3, 2021
    Assignee: Assembly Biosciences, Inc.
    Inventors: William W. Turner, Jr., Leping Li, Simon Nicolas Haydar, Mark G. Bures, Roopa Rai, Samson Francis, Lee D. Arnold
  • Hepatitis B core protein modulators
    Patent number: 10987360
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: April 27, 2021
    Assignee: Assembly Biosciences, Inc.
    Inventors: William W. Turner, Jr., Lee D. Arnold, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Hans Maag, Lynne Bannen
  • Hepatitis B core protein modulators
    Patent number: 10968211
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: April 6, 2021
    Assignees: Assembly Biosciences, Inc., INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: William W. Turner, Jr., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
  • Hepatitis B core protein allosteric modulators
    Patent number: 10947224
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: March 16, 2021
    Assignees: Indiana University Research and Technology Corporation, Assembly Biosciences, Inc.
    Inventors: William W. Turner, Jr., Lee Daniel Arnold, Hans Maag, Adam Zlotnick
  • CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME
    Publication number: 20200157070
    Abstract: The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.
    Type: Application
    Filed: March 1, 2018
    Publication date: May 21, 2020
    Inventors: William W. Turner, JR., Leping Li, Simon Nicolas Haydar, Mark G. Bures, Roopa Rai, Samson Francis, Lee D. Arnold
  • HEPATITIS B CORE PROTEIN MODULATORS
    Publication number: 20200131168
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Application
    Filed: May 30, 2019
    Publication date: April 30, 2020
    Inventors: William W. Turner, JR., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
  • HEPATITIS B CORE PROTEIN MODULATORS
    Publication number: 20190255067
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.
    Type: Application
    Filed: September 14, 2017
    Publication date: August 22, 2019
    Inventors: William W. Turner, JR., Lee D. Arnold, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Hans Maag, Lynne Bannen
  • Hepatitis B viral assembly effectors
    Patent number: 10273228
    Abstract: Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: April 30, 2019
    Assignees: Indiana University Research and Technology Corporation, Assembly Biosciences, Inc.
    Inventors: Lee Daniel Arnold, Hans Maag, William W. Turner, Jr.
  • Hepatitis B viral assembly effectors
    Patent number: 10220034
    Abstract: Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: March 5, 2019
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Adam Zlotnick, Lichun Li, William W. Turner, Jr., Samson Francis
  • Hepatitis B core protein allosteric modulators
    Patent number: 10183936
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: January 22, 2019
    Assignees: Indiana University Research and Technology Corporation, Assembly Biosciences, Inc.
    Inventors: William W. Turner, Jr., Lee Daniel Arnold, Hans Maag, Adam Zlotnick
  • HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS
    Publication number: 20180273521
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Application
    Filed: April 27, 2018
    Publication date: September 27, 2018
    Applicants: Indiana University Research and Technology Corporationt, Assembly Biosciences, Inc.
    Inventors: William W. Turner, JR., Lee Daniel Arnold, Hans Maag, Adam Zlotnick
  • Fluorescent-HAP: a diagnostic stain for HBV cores in cells
    Patent number: 10006913
    Abstract: Heteroaryldihydropyrimidine (HAP)-based fluorescent stains (compounds), as well as uses of such stains as diagnostic reagents, viral-tracking agents, and/or tools for drug discovery are described. The present invention relates to heteroaryldihydropyrimidine (HAP)-based fluorescent stains (compounds), as well as uses of such stains as diagnostic reagents, viral-tracking agents, and/or tools for drug discovery.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: June 26, 2018
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Adam Zlotnick, Lichun Li, Michael S. Van Nieuwenhze, William W. Turner
  • HEPATITIS B VIRAL ASSEMBLY EFFECTORS
    Publication number: 20180099952
    Abstract: Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.
    Type: Application
    Filed: April 15, 2016
    Publication date: April 12, 2018
    Applicants: Indiana University Research and Technology Corporation, Assembly Biosciences, Inc.
    Inventors: Lee Daniel Arnold, Hans Maag, William W. Turner, Jr.